Lundbeckfond Invest A/S - Aug 9, 2023 Form 4 Insider Report for IO Biotech, Inc. (IOBT)

Role
Director, 10%+ Owner
Signature
Lundbeckfond Invest A/S, by: /s/ Brian Burkavage, Attorney-in-Fact for Christian Elling, Managing Partner, and Lene Skole, Chief Executive Officer
Stock symbol
IOBT
Transactions as of
Aug 9, 2023
Transactions value $
$15,999,999
Form type
4
Date filed
8/11/2023, 09:22 PM
Previous filing
Nov 12, 2021
Next filing
Nov 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IOBT Common Stock Award $15M +7.9M +130.61% $1.90 14M Aug 9, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOBT Warrants (Right to Buy) Award $988K +7.9M $0.13* 7.9M Aug 9, 2023 Common Stock 7.9M $2.47 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition (as such term is defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023).

Remarks:

Christian Elling is Managing Partner of Lundbeckfonden Emerge, a division of Lundbeckfond Invest A/S, and currently serves as the representative of Lundbeckfond Invest A/S on the Issuer's board of directors, and therefore Lundbeckfond Invest A/S may be deemed a "director by deputization" of the Issuer.